RQ 02
Alternative Names: RQ-02Latest Information Update: 01 Dec 2023
At a glance
- Originator Red Queen Therapeutics
- Class Antivirals; Peptides
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 10 Oct 2023 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal) (Queen Therapeutics pipeline, October 2023)